Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - September 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces its sponsored placement in an editorial published on MarketScreener.com.
To view the full publication, "From Healthcare to Automation: Investing In Next AI Wave", please visit: https://www.marketscreener.com/news/from-healthcare-to-automation-investing-in-next-ai-wave-izozf-ai-dcbo-path-ce7d59dcd081f122.
"Artificial intelligence is moving beyond broad models and experimental tools. It is increasingly being applied to specific problems in defined industries where it can create measurable value. This includes sectors such as healthcare, enterprise software, defense, and industrial automation.
The focus is shifting from general AI to specialized systems that improve performance, streamline operations, or address long-standing inefficiencies. These applications are not theoretical. They are already being used in production environments and are gaining traction with both public and private sector customers.
As adoption increases, the companies building these targeted AI solutions are becoming more relevant. Their technologies are often embedded deeply into existing workflows, making them difficult to replace and potentially positioning them as long-term infrastructure in their respective markets. Investors looking beyond the hype will find several companies building targeted AI solutions with the potential to reshape entire industries… For investors, the opportunity lies in a company that combines disruptive technology, a strong intellectual property portfolio, and an expanding market. With IzoView nearing commercialization, Izotropic Corporation (OTCQB: IZOZF) represents a rare early-stage medtech play with the potential to define a new standard of care in breast cancer imaging and deliver meaningful long-term value."
About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
Email: jgagnon@izocorp.com
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265877
To view the full publication, "From Healthcare to Automation: Investing In Next AI Wave", please visit: https://www.marketscreener.com/news/from-healthcare-to-automation-investing-in-next-ai-wave-izozf-ai-dcbo-path-ce7d59dcd081f122.
"Artificial intelligence is moving beyond broad models and experimental tools. It is increasingly being applied to specific problems in defined industries where it can create measurable value. This includes sectors such as healthcare, enterprise software, defense, and industrial automation.
The focus is shifting from general AI to specialized systems that improve performance, streamline operations, or address long-standing inefficiencies. These applications are not theoretical. They are already being used in production environments and are gaining traction with both public and private sector customers.
As adoption increases, the companies building these targeted AI solutions are becoming more relevant. Their technologies are often embedded deeply into existing workflows, making them difficult to replace and potentially positioning them as long-term infrastructure in their respective markets. Investors looking beyond the hype will find several companies building targeted AI solutions with the potential to reshape entire industries… For investors, the opportunity lies in a company that combines disruptive technology, a strong intellectual property portfolio, and an expanding market. With IzoView nearing commercialization, Izotropic Corporation (OTCQB: IZOZF) represents a rare early-stage medtech play with the potential to define a new standard of care in breast cancer imaging and deliver meaningful long-term value."
About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
Email: jgagnon@izocorp.com
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265877